NCT00996671View on ClinicalTrials.gov

Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

November 6, 2009

Primary Completion Date

March 17, 2010

Study Completion Date

March 17, 2010

Conditions

Cancer

Interventions

DRUG

GSK2256098

focal adhesion kinase inhibitor given as a single dose

DRUG

Placebo

Placebo to be used as comparator for GSK2256098

Trial Locations (1)

3004

GSK Investigational Site, Melbourne

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY